# Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

Source: https://onco.cc/trials/nct05629234/  
OnCo record `nct05629234` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.

## Summary

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) is a phase 3 interventional study registered as NCT05629234 by AstraZeneca, with 37 participants enrolled, started 2023-05-08 and due to reach its primary completion in 2027-02-22. Interventions recorded: Osimertinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05629234
- Phase: 3
- Setting: ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
- Sponsor: AstraZeneca
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT05629234: https://clinicaltrials.gov/study/NCT05629234

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Parexel](https://onco.cc/companies/parexel/)

---
JSON: https://onco.cc/api/v1/entities/nct05629234.json